MedTrace Logo

Airway Dysfunction, Occlusions and Remodeling: COPD Patients and Mepolizumab

NCT07749001 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-08-06

No results posted yet for this study

Summary

The goal of this study is to evaluate the effect of mepolizumab on patients with COPD using MRI and CT imaging as well as breathing tests. The study will evaluate the response to this medication after 24 and 48 weeks of treatment. The main questions it aims to answer are:

1. Does mepolizumab improve ventilation defect percent as measured on 129-Xenon MRI in adults with COPD.
2. Does mepolizumab improve the amount of mucus plugs in the lungs as measured by lung CT in adults with COPD.

Participants will:

1. Take mepolizumab by subcutaneous injection every 4 weeks for the duration of the study.
2. Visit Robarts 4 times over 48 weeks for tests and imaging.

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

DRUG

Mepolizumab 100 MG Injection

mepolizumab 100mg will be administered subcutaneously once every 4 weeks starting at baseline visit-1 through to visit 4 (48 weeks).

Sponsors & Collaborators

  • Western University, Canada

    lead OTHER

Principal Investigators

  • Grace Parraga, PhD · Robarts Research Institute, The University of Western Ontario

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2028-02-28
Completion
2028-04-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07749001 on ClinicalTrials.gov